U.S. Markets closed

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6000+0.0500 (+3.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5500
Open1.5500
Bid1.5800 x 2200
Ask1.6000 x 800
Day's Range1.5500 - 1.6100
52 Week Range1.0900 - 22.5000
Volume90,241
Avg. Volume427,010
Market Cap7.812M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-23.1350
Earnings DateAug 11, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.50
  • InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    Business Wire

    InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,715,240 shares of its common stock at a purchase price of $1.75 per share. The Company also issued to the purchasers of such shares unregistered warrants to purchase up to 1,715,240 shares of common stock. The warrants have an exercise price of $1.62 per share, are exercisable immediately, and will expire five and one-half years from the date of issuance.

  • InVivo Therapeutics Announces $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    Business Wire

    InVivo Therapeutics Announces $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,715,240 shares of its common stock at a purchase price of $1.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the investors unregistered warrants to purchase up to 1,715,240 shares of common stock. The warrants have an exercise price of $1.62 per share, are exercisable immediately, and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about April 17, 2020, subject to the satisfaction of customary closing conditions.

  • InVivo Therapeutics Announces Closing of $7.0 Million Public Offering
    Business Wire

    InVivo Therapeutics Announces Closing of $7.0 Million Public Offering

    InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 2,545,455 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of $2.75 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering were approximately $7.0 million, before deducting the placement agent fees and estimated offering expenses payable by InVivo Therapeutics.